Regulatory risk is rising. Investors want guardrails, not hype. Three threads converge: FDA scrutiny on GLP-1 therapies, India’s patient-capital shift for deep tech, and the hardware-led cadence in consumer tech. The takeaway: durable, de-risked bets win runway.